A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multi-dose DDO-3055 Tablets in Healthy Subjects-Randomized, Double-blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial.
Latest Information Update: 07 Feb 2023
At a glance
- Drugs DDO 3055 (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 04 Mar 2021 New trial record